THE USE OF TOLTERODINE IN PATIENTS WITH RECURRENT CHRONIC CYSTITIS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the results of evaluation of effect of M-cholinoblocer tolterodine on the symptoms of lower urinary tract diseases (LUTD) and quality of life of patients with recurrent chronic cystitis. The study included 47 patients with chronic recurrent cystitis at acute stage with non-obstructive type of urination and LUTS. Group 1 included 23 women aged 45 to 56 years, who received tolterodine on the background of antibacterial therapy, taking into account the sensitivity of the isolated strain. Control group included 24 patients who received standard antibacterial therapy, also taking into account the sensitivity of the pathogen, and spasmolytics. The groups were almost homogeneous and did not differ on the basic characteristics. Analysis of the results of the study showed that tolterodine as a symptomatic therapy can reduce the time of rehabilitation. Therapy with tolterodine has shown clinical efficacy for 85.7% of women, has improved the quality of life by 24.8% compared with the control group, and provided relief of urgent and irritative symptoms in the short time.

Full Text

Restricted Access

References

  1. Скрябин Г.Н., Александров В.П., Кореньков Д.Г. Циститы. СПб., МАПО, 2006.
  2. Foxman B., Somsel P., Tallman P., Gillespie B., Raz R. et al. Urinary tract infection among women aged 40 to 65: behaviorial and sexual risk factors. J. Clin. Epidimiol., 2001;54(7):710—718.
  3. Hooton T.M. Reccurent urinary tract infection in women. Int. J. Antimicrob. Agents. 2001; 17(4):259—268.
  4. Lundstredt A. C. et al. Inherited susceptibility to acute pyelonephritis: a family study of urinary tract infection. J. Infect Dis. 2007;195(8): 1227—1234.
  5. Hooton T.M. Reccurent urinary tract infection in women. Int. J. Antimicrob. Agents. 2001; 17(4):259—268.
  6. Nicolle L.A. Asimptomatic bacteriuria in the elderly. Infect. Dis. Clin. North. Am. 1997; 11(3): 647-662.
  7. Суфияров А.Д. Актуальные проблемы консервативной урологии. Менопаузальный цистит. Цисталгия. Под ред. Р. Х. Галеева. Казань: МЕДДОК, 2007. 128 с.
  8. Damiano R., Cicione A. The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. Adv. Urol. 2011; 3(5): 223-232.
  9. Geppetti P., Nassini R., Materazzi S., Benemei S. The concept of neurogenic inflammation. BJU Int. 2008; 101(Suppl.3):2-6.
  10. Parsons C.L., Lilly J.D., Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J. Urol. 1991; 145(4):732-735.
  11. Siracusano S., Cucchi S., Ciciliato S. et al. Urinary levels of giycosaminoglycans in patients with idiopathic detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(12): 1477-1480.
  12. Nomiya M., Sagawa K., Yazaki J. et al. Increased bladder activity is associated with elevated oxidative stress markers and proinflammatory cytokines in a rat model of atherosclerosis-induced chronic bladder ischemia. Neurourol. Urodyn. 2012;31(1):185-189.
  13. Avelino A., Cruz C., Nagy I. et al. Vanilloid receptor expression in the rat urinary tract. Neuroscience. 2002; 109 (4):787-798.
  14. Arya L. A. et al. Evidence of bladder oversensitivity in the absence of an infection in premenopausal women with a history of recurrent urinary tract infections. BJU Int. 2011;30:1464-410.
  15. Nile C.J., Gillespie J.I. Interactions between cholinergic and prostaglandin signaling elements in the urothelium: role for muscarinic type 2 receptors. Urology. 2012;79(1):240.
  16. Tyagi P., Barclay D., Zamora R. et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int. Urol. Nephrol. 2010;42(3):629-635.
  17. Groat W.C., Yoshimura N. Afferent nerve regulation of bladder function in health and disease. Handb. Exp. Pharmacol. 2009; (194):91-138.
  18. Hawthorn M.H., Chapple C.R., Cock M. et al. Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br. J. Pharmacol. 2000;129(3):416-419.
  19. Mukerji G., Yiangou Y., Grogono J. et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J. Urol. 2006;176(1):367—373.
  20. Nilvebrant L., Andersson K.E., Gillberg P.G. et al. Tolterodine-a new bladder-selective antimuscarinic agent. Eur. J. Pharmacol. 1997; 327(2-3): 195-207.
  21. Appell R.A., Abrams P., et al. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J. Urol. 2001; 19: 141-147.
  22. Ejernaes K. Bacterial characteristics of impotance for recurrent urinary tract infections caused by Escherichia coli. Dan Med Bull. 2011; 58(4): В4187.
  23. Sellers D.J., McKay N. Developments in the pharmacotherapy of the overactive bladder. Cur Opt Urol. 2007;17(4):223-230.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies